INVESTOR OVERVIEWCorporate ProfileRhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity. More >>Recent NewsMore >>06/20/18Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering06/18/18Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering06/18/18Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity RYTM (Common Stock) $26.42 0.25 (0.96%)06/20/18 4:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and SourcesUpcoming EventsMore >>There are currently no events scheduled.